- Intended Audience: Pharmacists interested in genomic medicine
- Universal Activity Number: 0012-0000-20-032-H04-P
- Contact Hours: 3
- Program Fees: 50.00
- Dates Available: 05/06/2020 – 05/06/2023
- Activity Type: Knowledge
Experts in the field of genomic medicine will provide an overview of how to implement precision medicine in your health system and whether or not polygenic risk scores and preventative genomics deliver will play a role in precision medicine. The current and future landscape surrounding testing newborns will also be discussed. Content is based on the Precision Medicine Conference hosted February 2020.
This course is approved by the Florida Board of Pharmacy for 3 consultant recertification hours.
At the completion of this activity, the participant will be able to:
- Describe the current state of knowledge and emerging trends in precision medicine across a broad range of therapeutic areas including pharmacogenomics, preventive disease risk assessment, universal genomic screening, newborn screening, precision oncology, and the use of microbial genomics in infection control.
- Demonstrate the regulatory oversight and need for application of evidence-based medicine principles in precision medicine and clinical pharmacogenomics.
- Describe challenges and solutions for the application of precision medicine in patient care.
- Compare and contrast approaches to implementing precision medicine in a variety of clinical settings.
The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.
- April Schultz, PharmD, RPh
- David R. Nelson, MD
- Eimear E. Kenny, PhD
- Stephen Rich, PhD
- Sonja A. Rasmussen, MD, MS
The following speakers, reviewers, and planning committee members have disclosed the following:
- James Crawford, MD, PhD has disclosed that he is “President” of Northwell Health Genomics Alliance, a Northwell joint venture with OPKO/ BioRefeence Laboratories for the performance of genetic/genomic lab testing for Northwell.
- Kurt D. Christensen, PhD has disclosed that he has received grant/ research support from Sanford Health (Sanford Imagenetics).
- Matthew Farrer, PhD has disclosed that he is a stock shareholder and has shares in Neurocode Labs Inc.
Schedule of Activities and Requirements for Successful Course Completion
Review the course material, receive a 70% or higher on the post-test, and submit a course evaluation.
- The University of Florida College of Pharmacy will report CPE credit to CPE Monitor and CE Broker when applicable. If you would like a paper statement of credit, you may print it from your NABP e-profile.
- All pharmacists and pharmacy technicians maintain their own license and/or certification and it is their responsibility to follow up with the Office of Continuing Education at the University of Florida if any CE credit discrepancies are found.
- It is at the University’s discretion to award or deny credit to a late claiming participant (i.e. after 60 days of the participant engaging in a CPE activity) as it is the University’s CE activity and the provider needs to ensure the requirements necessary for credit are successfully completed.
- The University may request access to CPE Monitor® if the activity in question occurred within the previous 6 months and with an appropriate reason for access, i.e. power outage, etc.
Program Financial Support
This course received no financial program support.
Computer and Internet access are required to complete this course. Course content is provided via Canvas.
This course in its entirety is copyrighted by the University of Florida Continuing Pharmacy Education and may not be duplicated or reproduced for any other purpose without specific written permission.
The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.